Featured tickers: $ACAD $ACT $AGIO $AGN $AVNR $ECYT $ESPR $GILD $GLMD $SLXP $SRPT $TKMR
The day you don't relish in other ppl's losses+do not envy gains, it will make you a better trader/investor. #beentheredonethat
— Dirk Haussecker (@RNAiAnalyst) September 22, 2014 @adamfeuerstein not to repeat myself, but I like their low key approach. Science over hype. I wish CG $SRPT had done the same.
— Alfredo Fontanini (@AF_biotech) September 22, 2014 It was nice of $ACAD to tell JP Morgan that info exclusively, btw.
— Brad Loncar (@bradloncar) September 22, 2014 Wonder if the VP at $AVNR knew a week ago when he sold if there was an offering coming:)
— Festo (@Festo50) September 22, 2014 #BPA14 financial landscape panel talking about the tide going out....know it will happen, don't know when, want to have capital on hand
— Laura Strong (@scientre) September 22, 2014 So Actavis wants to buy Allergan, which wants to buy Salix, which is trying to invert through Cosmo deal. The biopharma orgy.
— John Carroll (@JohnCFierce) September 23, 2014 Interesting how companies now write press releases intended specifically for algos - $GLMD didnt get fda "approval' - meaningless fast track
— Ian Estepan (@ianestepan) September 23, 2014 $gild TAF: yet another blockbuster that fills a genuine need
— biotechnicality (@biotechnicality) September 24, 2014 @ColfaxCapital @Sport234a I consider not being down 5%+ holding up for bios. I am clearly grading on a curve.
— David Sobek (@dsobek) September 25, 2014 Incredible but true: The median price of the 100 top selling drugs in the USA increased 7-fold in 4 years: http://t.co/P8e94vVlDT $GILD
— Jon Gardner (@JonEPVantage) September 25, 2014 Robyn K is going to have "4 picks" on Fast Money tonight...again.
— Brad Loncar (@bradloncar) September 25, 2014 is it transition time, from Buying The Dips, to Selling The Rips? Is it?
— happycamper (@happyycamperr) September 25, 2014 $AGIO wow ... the next $PCYC is here.
— avidresearch (@avidresearch) September 26, 2014 Why restrict UK & US media access? MT @Boehringer: Non-US, Non-UK PRESS: visit our interactive zone rich w/ multimedia about #cancer #ESMO14
— Pieter Droppert (@3NT) September 26, 2014 $ESPR going bananas
— Juan P. Serrate, DVM (@JPZaragoza1) September 26, 2014 ,@NebraskaMed fires 2 employees for inappropriately accessing #Ebola patient Rick #Sacra med records, violating #HIPAA regs $TKMR #pharma
— Donna Young (@ScripDonnaDC) September 27, 2014 @lipscrl It's harder to set up the trades and leave them on auto, but the volatility allows the trades to still be there
— DeadCatBill (@getbillasap) September 27, 2014 .@AndyBiotech Where FDA is slow, hacker/DIY community fills void. This has been true in personal genomics (for better/worse) for a while now
— David Maizenberg (@biologypartners) September 27, 2014 $ECYT @EBUYUKARSLAN @BayAreaBiotechI @DPDResearch sure feel free to accept whatever co tells you at face value w/o critical analysis ;)
— Andy Biotech (@AndyBiotech) September 27, 2014 I’ve violated my no work tweets on weekend rule. off for a long run with max and then Derek Jeter’s last game. have a good one, guys.
— Adam Feuerstein (@adamfeuerstein) September 28, 2014 
RSS Feed
